title: Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis.
abstract: OBJECTIVE
  We compared the efficacy of a new nonsteroidal antiinflammatory drug (NSAID) eye drop, 0.1% bromfenac sodium (Bromfenac), with that of an antiallergic agent, 0.1% pemirolast potassium (Pemirolast), in the treatment of seasonal allergic conjunctivitis in Japanese patients.
  
  
  METHODS
  Twenty-two subjects with seasonal allergic conjunctivitis were enrolled in the study. One eye was treated with Bromfenac eye drops and the contralateral eye was treated with Pemirolast eye drops for 1 week. Subjective ocular symptoms and objective ocular signs evaluated by slit-lamp examination were scored and recorded before and after treatment.
  
  
  RESULTS
  Both drugs significantly decreased ocular signs after 1 week, but not symptoms. No significant differences in subjective symptoms or objective signs were observed between the two drugs. Ten patients (45.5%) selected Bromfenac as more effective, nine patients (40.9%) selected Pemirolast, and three patients found no difference in efficacy between the two drugs.
  
  
  CONCLUSIONS
  Bromfenac sodium is as safe and effective for the treatment of allergic conjunctivitis as pemirolast potassium.
authors.affiliation: Department of Ophthalmology, Tokyo Dental College, Chiba, Ichikawa, Japan.
authors.forename: Minori
authors.initials: M
authors.lastname: Miyake-Kashima
authors.forename: Yoji
authors.initials: Y
authors.lastname: Takano
authors.forename: Mari
authors.initials: M
authors.lastname: Tanaka
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Satake
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Kawakita
authors.forename: Murat
authors.initials: M
authors.lastname: Dogru
authors.forename: Naoko
authors.initials: N
authors.lastname: Asano-Kato
authors.forename: Kazumi
authors.initials: K
authors.lastname: Fukagawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Fujishima
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D001577:Benzophenones / Q000008:administration & dosage / Q000627:therapeutic use*; D001969:Bromobenzenes / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D003233:Conjunctivitis, Allergic / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006633:Histamine Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000008:administration & dosage / Q000627:therapeutic use*; D012449:Safety; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001577:Benzophenones; D001969:Bromobenzenes; D006633:Histamine Antagonists; D009883:Ophthalmic Solutions; D011725:Pyridines; D011744:Pyrimidinones; C055139:pemirolast; D007073:Immunoglobulin E; C053083:bromfenac